Regression was performed on chosen microarray data, with the slope and P value for the line of best fit reported also as the r2 worth for the connection. All statistical analyses were performed with GraphPad Prism version 6.00 (GraphPad Computer software). Study approval. All patient samples were deidentified, plus the project was exempted by the Duke University Wellness Program Institutional Review Board (protocol ID 00034541). All animal procedures were authorized by the Duke University Institutional Animal Care and Use Committee (protocol A278-11-11).Acknowledgments We thank Michael Hogarty, the Children’s Oncology Group Neuroblastoma Biology Subcommittee, Wendy London, and Evan Plunkett for giving patient tissue and serum samples. We thank Linda Valentijn, Paul Yu, Harriett Stadt, Mary Hutson, Margaret Kirby, and Lisa Crose for delivering reagents. We thank Lindsey Morgan and Terri Lucas for coordinating our animal facility use. We thank Julie Fuller for tissue processing. We are grateful to Tam How, Catherine Gatza, Alison Meyer, Alisha Holtzhausen, Catherine Lavau, Rebekah Moehring, Jennifer Elderbroom, Rachel Hesler, and Jasmine Nee for technical assistance and Cheryl Alles for superior clerical assistance. We are grateful to Daniel Wechsler, Dona Chikaraishi, Christopher Kontos, and Julio Ramirez for invaluable mentoring throughout this project. This operate was supported in part by NIH grants F30 CA168043-01 (to E.H. Knelson), R01-CA136786 (to G.C. Blobe), and R01-CA135006 (to G.C. Blobe). Received for publication March 1, 2013, and accepted in revised form August eight, 2013. Address correspondence to: Gerard C. Blobe, Duke University Medical Center, Box 91004, Durham, North Carolina 27708, USA. Phone: 919.668.1359; Fax: 919.681.6906; E-mail: [email protected] 123 Number 11 Novemberhttp://jci.orgresearch article1. National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) Database. NIH Web site. Accessed August 30, 2013. 2. Mullassery D, Dominici C, Jesudason EC, McDowell HP, Losty PD. Neuroblastoma: contemporary management. Arch Dis Kid Educ Pract Ed. 2009;94(six):17785. 3. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106120. 4. De Bernardi B, et al. Retrospective study of childhood ganglioneuroma. J Clin Oncol. 2008; 26(10):1710716. 5. Retrosi G, et al. Morbidity after ganglioneuroma excision: is surgery essential Eur J Pediatr Surg. 2011;21(1):337. six. Janoueix-Lerosey I, Schleiermacher G, Delattre O. Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene. 2010;29(11):1566579. 7. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202211. 8. Brodeur GM. Neuroblastoma: biological CA Ⅱ manufacturer insights into a clinical enigma. Nat Rev Cancer. 2003; three(three):20316. 9. Seeger RC, et al. Association of several copies on the N-myc oncogene with Reactive Oxygen Species Gene ID speedy progression of neuroblastomas. N Engl J Med. 1985; 313(18):1111116. 10. Schwab M, et al. Amplified DNA with restricted homology to myc cellular oncogene is shared by human neuroblastoma cell lines as well as a neuroblastoma tumour. Nature. 1983;305(5931):24548. 11. Westermark UK, Wilhelm M, Frenzel A, Henriksson MA. The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol. 2011;21(four):25666. 12. Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett. 2010;293(2):14457. 13. Matthay KK, et al. Long-term results for ch.